Here is a brief description of how 20 constituents in the HAN-GINS
Indxx Healthcare Innovation UCITS ETF (WELL) are involved in the
fight against COVID-19:
-
Regeneron Pharmaceuticals, Inc.
Regeneron has identified hundreds
of virus-neutralizing antibodies and have plans to initiate large-scale
manufacturing by mid-April with an antibody cocktail therapy. This biotech leader is at the forefront of
the race to find a vaccine for COVID-19.
It is one of WELL’s largest 3 holdings (14th April 2020). [1]
-
Smith & Nephew plc
Smith and Nephew has a contract with
the U.K. government to build a new ventilator specifically designed for the
large-scale production needed to combat the spread of COVID-19. [2]
-
QIAGEN NV
The US Food and Drug
Administration (FDA) has granted an emergency use authorization
to Qiagen (NYSE:QGEN) for a diagnostic test that the company said can
differentiate among COVID-19 and 20 other respiratory diseases [3]
-
bioMerieux SA
bioMérieux, a world leader in the
field of in vitro diagnostics, has announced the forthcoming launch of three
different tests to address the COVID-19 epidemic and to meet the different
needs of physicians and health authorities in the fight against this emerging
infectious disease. [4]
-
Bio-Rad
Laboratories, Inc. Class A
Bio-Rad's products are used in
research and clinical laboratories around the world, contributing to
advancement of COVID-19 research, SARS-CoV-2 screening assays, and vaccine
development. [5]
-
BioTelemetry,
Inc.
BioTelemetry, Inc. (NASDAQ:BEAT),
a leading remote medical technology company focused on the delivery of health
information to improve quality of life and reduce cost of care, recently announced
the activation of an expanded service using its Mobile Cardiac Outpatient
Telemetry (MCOT(TM)) to monitor life-threatening QT prolongation in COVID-19
patients. [6]
-
Boston
Scientific Corporation
Boston Scientific has collaborated
with hospitals, universities and industry peers to find new and innovative ways
to address the urgent demand for protective personal equipment (PPE) and
ventilators. [7]
-
DiaSorin S.p.A.
DiaSorin Molecular LLC, a division
of DiaSorin S.p.A., has received the Emergency Use Authorization (EUA) from the
FDA for their Simplexa™ COVID-19 Direct kit. The kit provides a
sample-to-answer test for the detection of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, directly from
nasopharyngeal swab specimens. [8]
-
Alnylam Pharmaceuticals, Inc
Vir Biotechnology,
Inc. (Nasdaq: VIR) and Alnylam Pharmaceuticals, Inc. (Nasdaq:
ALNY) has announced an expansion of their existing collaboration to include the
development and commercialization of RNAi therapeutics targeting SARS-CoV-2,
the virus that causes the disease COVID-19. [9]
-
Avanos Medical, Inc.
Avanos Medical is supporting the
healthcare sector by adjusting production and working with their suppliers to
produce more respiratory health products to help treat COVID-19 patients. [10]
-
ResMed Inc.
ResMed are focused on delivering
the ventilation therapy that is essential to treat the respiratory
complications of COVID-19. [11]
-
Eiken
Chemical Co., Ltd.
Eiken Chemical Co., Ltd. (Headquarters:
Taito Ward, Tokyo) is moving forward with the development of a reagent for
detecting the COVID-19 coronavirus using the LAMP method*, a gene amplification
method developed exclusively by Eiken Chemical. [12]
-
Hologic, Inc.
Hologic’s Molecular Test for the
Novel Coronavirus, SARS-CoV-2, has received FDA emergency use authorization. [13]
-
Luminex Corp
In response to the global outbreak,
Luminex has developed multiple solutions to enhance its NxTAG® and
ARIES® testing offerings in order to automate and facilitate the detection
of coronavirus. As a high-throughput, more comprehensive option, they have
developed the NxTAG® CoV Extended Panel, which can detect SARS-CoV-2,
and was authorized by the US FDA and Health Canada for Emergency Use
Authorization (EUA). [14]
-
Medtronic Plc
Medtronic plc (NYSE:MDT), the
global leader in medical technology, today announced its Medtronic Care
Management Services (MCMS) business is launching two new solutions
designed to help assess, monitor, and triage support for patients who may be
concerned about COVID-19 and their respiratory symptoms. It has already
launched its new Respiratory Infectious Disease Health Check to
existing MCMS customers, and it is now launching a new COVID-19 Virtual Care
Evaluation and Monitoring solution available to U.S. health systems, health
plans and employers. It is also helping with the production and delivery
of more ventilators globally. [15]
-
Meridian Bioscience, Inc.
Meridian Bioscience,
Inc. (NASDAQ: VIVO) announced that it has increased its commitment to the
global fight against COVID-19 by making available zero cost samples of the
company’s proprietary technologies to developers and manufacturers of molecular
assays for COVID-19 detection. [16]
-
Adaptive Biotechnologies Corp.
Microsoft MSFT and Adaptive
Biotechnologies ADPT recently extended their partnership in a bid to aid public
health officials and researchers to access and track data pertaining to
COVID-19 patient immune responses. [17]
-
Health Catalyst, Inc.
Health Catalyst’s growing suite of
COVID-19 Solutions capabilities includes identifying the location of patients
who have tested positive for COVID-19 as well as other patient, clinician and
staff interactions and exposures to allow for infectious disease
surveillance and automated monitoring for “hot-spots” using local geo-mapping. [18]
-
Quidel Corporation
The Lyra SARS-CoV-2 Assay is a
real-time RT-PCR assay intended for the in vitro qualitative
detection of human coronavirus SARS-CoV-2 from viral RNA extracted from
nasopharyngeal (NP) or oropharyngeal (OP) swab specimens from patients with
signs and symptoms of COVID-19. [19]
-
Twist Bioscience Corp
Twist Bioscience has partnered with
Vanderbilt University Medical Center to supply critical products and identify antibody
therapeutics for COVID-19. [20]